

ORIGINAL ARTICLE

Triglycerides and glucose index: A useful indicator of insulin resistance[☆]



Gisela Unger^a, Silvia Fabiana Benozzi^a, Fernando Perruzza^b,
Graciela Laura Pennacchiotti^{a,b,*}

^a *Bioquímica Clínica I, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, Bahía Blanca, Provincia de Buenos Aires, Argentina*

^b *Hospital Municipal de Agudos "Dr. Leónidas Lucero", Bahía Blanca, Provincia de Buenos Aires, Argentina*

Received 10 April 2014; accepted 23 June 2014

KEYWORDS

Insulin resistance;
Metabolic syndrome;
Triglycerides
and glucose index

Abstract

Introduction: Insulin resistance assessment requires sophisticated methodology of difficult application. Therefore, different estimators for this condition have been suggested. The aim of this study was to evaluate the triglycerides and glucose (TyG) index as a marker of insulin resistance and to compare it to the triglycerides/HDL cholesterol ratio (TG/HDL-C), in subjects with and without metabolic syndrome (MS).

Materials and methods: An observational, cross-sectional study was conducted on 525 adults of a population from Bahía Blanca, Argentina, who were divided into two groups: *with MS* (n = 89) and *without MS* (n = 436). The discriminating capacities for MS of the TyG index, calculated as $\text{Ln}(\text{TG} [\text{mg/dL}] \times \text{glucose} [\text{mg/dL}]/2)$, and the TG/HDL-C ratio were evaluated. Pre-test probability for MS was 30%.

Results: The mean value of the TyG index was higher in the group *with MS* as compared to the group *without MS* and its correlation with the TG/HDL-C ratio was good. The cut-off values for MS in the overall population were 8.8 for the TyG index (sensitivity = 79%, specificity = 86%), and 2.4 for the TG/HDL-C ratio (sensitivity = 88%, specificity = 72%). The positive likelihood ratios and post-test probabilities for these parameters were 5.8 vs 3.1 and 72% vs 58% respectively. The cut-off point for the TyG index was 8.8 in men and 8.7 in women; the respective values for TG/C-HDL were 3.1 in men and 2.2 in women.

Conclusions: The TyG index was a good discriminant of MS. Its simple calculation warrants its further study as an alternative marker of insulin resistance.

© 2014 SEEN. Published by Elsevier España, S.L.U. All rights reserved.

[☆] Please cite this article as: Unger G, Benozzi SF, Perruzza F, Pennacchiotti GL. Índice triglicéridos y glucosa: un indicador útil de insulinorresistencia. Endocrinol Nutr. 2014;61:533–540.

* Corresponding author.

E-mail address: grapen@uns.edu.ar (G.L. Pennacchiotti).

PALABRAS CLAVE

Insulinorresistencia;
Síndrome metabólico;
Índice triglicéridos
y glucosa

Índice triglicéridos y glucosa: un indicador útil de insulinorresistencia**Resumen**

Introducción: La evaluación de la insulinorresistencia requiere de metodología sofisticada de difícil aplicación. Por lo cual se han sugerido distintos estimadores de esta condición. El objetivo de este estudio fue evaluar el índice triglicéridos y glucosa (TyG) como marcador de insulinorresistencia y compararlo con la relación triglicéridos y colesterol-HDL (TG/C-HDL), en individuos con y sin síndrome metabólico (SM).

Material y métodos: Se realizó un estudio observacional, transversal, en 525 individuos adultos de una población de Bahía Blanca, Argentina, quienes fueron divididos en dos grupos: con SM (n = 89) y sin SM (n = 436). Se evaluaron las capacidades discriminativas para SM del índice TyG, calculado como $\text{Ln}(\text{TG} [\text{mg/dL}] \times \text{glucosa} [\text{mg/dL}]/2)$, y de la relación TG/C-HDL. Probabilidad pretest para SM = 30%.

Resultados: El valor medio del índice TyG fue mayor en el grupo con SM comparado con el grupo sin SM y fue buena su correlación con TG/C-HDL. Los puntos de corte para SM en la población total fueron: 8,8 para el índice TyG (sensibilidad = 79%, especificidad = 86%), y 2,4 para la relación TG/C-HDL (sensibilidad = 88%, especificidad = 72%). Las razones de probabilidad y probabilidades posttest positivas para dichos parámetros fueron 5,8 vs. 3,1 y 72% vs. 58%, respectivamente. El punto de corte para el índice TyG en hombres fue 8,8 y en mujeres 8,7; los valores respectivos para TG/C-HDL fueron 3,1 en hombres y 2,2 en mujeres.

Conclusiones: El índice TyG fue un buen discriminante de SM. La simplicidad de su cálculo justifica profundizar su estudio como marcador alternativo de insulinorresistencia.

© 2014 SEEN. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Insulin resistance (IR) involves decreased cell sensitivity to insulin and is a central characteristic of metabolic syndrome (MS).¹ IR predisposes to several metabolic disorders including hyperglycemia, high blood pressure, and dyslipidemia, all of them strongly associated with diabetes, atherosclerosis, and cardiovascular disease.

The evaluation of IR requires sophisticated methods which are not available for use in daily clinical practice.² Hyperinsulinemic–euglycemic clamp is the direct method to measure IR and is considered the “gold standard” procedure, but it is difficult to perform in daily practice. Several surrogate markers have therefore been proposed, including the homeostatic model assessment of IR (HOMA-IR), one of the most widely used. HOMA-IR is calculated based on the measurement of fasting glucose and insulin levels.³ There are two issues to be considered with regard to insulin. On the one hand, insulin has a high biological variability (within- and between-subject variability of 21.1% and 58.3% respectively),⁴ and on the other hand, its measurement has yet to be standardized.^{5,6} These two aspects have a direct impact on the estimation of IR using the HOMA-IR index and other formulas which have been developed using insulin level in their calculations (QUICKI, FGIR, Raynaud, reciprocal insulin).⁷

Because of these difficulties, attempts have been made to identify other parameters that could be helpful for assessing IR. In fact, indices to determine insulin action based on lipids may help identify subjects with IR.⁸ Hypertriglyceridemia and hypoalphalipoproteinemia is the characteristic dyslipidemia in subjects with IR.^{9,10} Although no definitive explanation is still available for the correlation

between hypertriglyceridemia and IR, it has been reported that elevated triglyceride (TG) levels interfere with glucose metabolism in muscles,¹¹ a finding consistent with the hypothesis that TG elevation in serum and tissue is related to decreased insulin sensitivity.¹² In this regard, the relationship between plasma levels of TG and HDL cholesterol (TG/HDL-C) has been proposed as a useful alternative for estimating insulin action,¹³ and in 2010 Guerrero et al. showed that the product of TG and glucose in plasma, the so-called triglycerides and glucose index (TyG), could be a useful estimate of IR.¹⁴ This index was compared to the hyperinsulinemic–euglycemic clamp, and was shown to have good sensitivity and specificity for IR detection. Its association with carotid atherosclerosis has been shown.¹⁵ Reaven et al. also showed the index to be similar to the TG/HDL-C ratio and comparable to estimates using fasting insulin levels.⁸

Salazar et al., based on a study conducted on an Argentine population, suggested that both the diagnosis of MS and the TG/HDL-C ratio are adequate for identifying subjects with IR.¹⁶

Based on the foregoing and considering MS as a pre-diabetic state or a state of decreased cell sensitivity to insulin,^{17–20} the TyG index was assessed as an IR marker and was compared to the TG/HDL-C ratio in subjects with and without MS in an adult population from Bahía Blanca, Argentina.

Patients and methods

An observational, cross-sectional study was conducted on a working population attending during the 2009–2011

period the preventive medicine department of Dr. Leónidas Lucero Hospital in Bahía Blanca, province of Buenos Aires, Argentina to undergo tests necessary for obtaining the working health certificate required by the Bahía Blanca local authority.

The estimated sample size to assess diagnostic tests with paired observations, assuming a 95% confidence level, 90% power, and a 30% prevalence of MS,²¹ was 454 subjects. In order to ensure this minimum sample size, 525 adult subjects (329 men and 196 women) aged 18–68 years were enrolled into the study.

Pregnant women and subjects with inflammatory and infectious conditions, taking anti-inflammatory treatment and who had practiced strenuous exercise on the days prior to blood sampling were excluded from the study. Subjects with values of high sensitivity C-reactive protein greater than 10.0 mg/L, suggesting the presence of a significant inflammatory condition, were also excluded.²²

All subjects were evaluated by medical staff using a questionnaire and a clinical examination, according to the procedure of the preventive medicine department.

The data recorded included: age, sex, smoking, medication received (hypoglycemic, antihypertensive, lipid-lowering, anti-inflammatory and other drugs), weight, height, waist circumference, body mass index, blood pressure, and observations made at the clinical examination.

Anthropometric measures were taken using standard procedures.²³ Waist circumference (cm) was measured halfway between the lower lateral margin of the last rib and the anterior superior region of the iliac crest while standing, using a flexible, not distensible measuring tape. Body mass index was calculated as weight (kg)/height (m)². Blood pressure was measured using a sphygmomanometer and recorded in mmHg.

Blood samples for biochemical tests were drawn in the morning, after a 12 h fast, by puncturing an antecubital vein, and were collected into tubes containing anticoagulant (heparin sodium).

All measurements were performed in an ADVIA1200 autoanalyzer (Siemens Medical Healthcare, Germany) using reagents of the same manufacturer. Plasma glucose levels were measured using a glucose-oxidase/Trinder's enzymatic colorimetric method with an end-point reaction. TG levels were measured using a glycerol-phosphate-oxidase/Trinder's enzymatic colorimetric method, with no serum blank, with an end-point reaction. HDL-C was measured using a direct catalase elimination method with a two-point kinetic reaction. High sensitivity C-reactive protein was tested using an immunoturbidimetric procedure.

The TyG index was calculated as the natural logarithm (Ln) of the product of plasma glucose and TG using the formula: $\text{Ln}(\text{TG} [\text{mg/dL}] \times \text{glucose} [\text{mg/dL}]/2)$.¹⁴ The TG/HDL-C ratio was calculated.

Study participants were divided into two groups: *with MS* (n=89, 64 men and 25 women) and *without MS* (n=436, 265 men and 171 women) using the criteria for MS of the National Heart, Lung, and Blood Institute and the American Heart Association,²⁴ according to which this condition is diagnosed as the presence of three or more of the following risk factors: abdominal obesity (waist

circumference >102 cm in men and >88 cm in women), hypertriglyceridemia (TG \geq 150 mg/dL or drug treatment for hypertriglyceridemia), low HDL-C level (<40 mg/dL in men and <50 mg/dL in women or drug treatment for decreased HDL-C), high blood pressure (BP \geq 130/85 mmHg or drug treatment for hypertension), impaired fasting glucose (fasting glucose \geq 100 mg/dL or drug treatment for hyperglycemia).

Statistical and epidemiological analysis of data was performed using the Statistical Package for Social Sciences for Windows (version 15.0, Chicago, IL, USA) and the Program for Epidemiological Analysis of Tabulated Data (version 3.1. Xunta de Galicia, Pan American Health Organization). The normality of the variables was verified using a Kolmogorov–Smirnov test. A Chi-square test was used to compare proportions. To compare mean values of parametric variables, a Student's *t* test, an ANOVA test, and Cohen's "d" to assess effect size²⁵ were used. Medians of non-parametric variables were compared using a Mann–Whitney test and Cliff's delta²⁶ to assess effect size. Correlation between the TyG index and the TG/HDL-C ratio was calculated using Spearman's rho. ROC curves were constructed, the area under the curve (AUC) of both parameters was compared using the DeLong method,²⁷ and the cut-off points with the greatest discriminatory capacity for MS were obtained. The sensitivity, specificity, odds ratio, and post-test probability of those cut-off points were estimated, with a pre-test probability of 0.30 in the overall population being assumed for MS, 0.34 in men and 0.25 in women.²¹

Differences were considered significant for a value of *p* less than 5%.^{28,29}

The study was approved by the ethics committee of Dr. Leónidas Lucero Hospital, and informed consent was obtained from all participating subjects.

Results

Table 1 shows the results of the assessed variables found in both groups (*with and without MS*), which were significantly different.

As shown in Table 2, the group *with MS* had higher values of the mean TyG index and median TG/HDL-C ratio as compared to the group *without MS*.

Table 3 gives the percentiles of the TyG index in both groups, showing that the value of the 50th percentile of the TyG index in the group *with MS* agreed with the value of the 90th percentile in the group *without MS*.

As shown in Fig. 1, the mean value of the TyG index increased as the number of MS components (*p*=0.000) in the total study population increased. There was a good correlation between the TyG index and the TG/HDL-C ratio (Spearman's rho=0.896), and the AUC for both parameters was greater than 0.75. Fig. 2 shows that there were no significant differences (*p*=0.343) between the AUC obtained for the TyG index (0.88; 95% CI=0.84–0.92) and the AUC for the TG/HDL-C ratio (0.85; 95% CI=0.81–0.90) as regards discriminating for MS, with the value of the TyG index of 8.8 and the value of 2.4 for the TG/HDL-C ratio showing the greatest sensitivity and specificity for discriminating MS in the study population.

Table 1 Results of the variables tested in the assessed groups (with and without metabolic syndrome).

Variable	Group		p
	With metabolic syndrome (n = 89)	Without metabolic syndrome (n = 436)	
Men/women	64/25	265/171	0.050
Age (years)			
Men	46 (14)	32 (17)	0.000
Women	45 (14)	34 (15)	0.000
Total	45 (15)	33 (16)	0.000
Waist circumference (cm)			
Men	180 (11)	884 (15)	0.000
Women	105 (19)	73 (16)	0.000
Total	107 (11)	82 (20)	0.000
Diastolic blood pressure (mmHg)			
Men	90 (20)	70 (10)	0.000
Women	80 (18)	60 (10)	0.000
Total	80 (15)	68 (10)	0.000
Systolic blood pressure (mmHg)			
Men	130 (30)	112 (20)	0.000
Women	120 (30)	110 (20)	0.000
Total	130 (30)	110 (20)	0.000
Triglycerides (mg/dL)			
Men	176 (92)	94 (60)	0.000
Women	158 (91)	84 (45)	0.000
Total	169 (97)	89 (57)	0.000
HDL cholesterol (mg/dL)			
Men	38 (10)	46 (16)	0.000
Women	46 (12)	57 (19)	0.000
Total	39 (12)	51 (18)	0.000
Glucose (mg/dL)			
Men	103 (22)	89 (13)	0.000
Women	101 (21)	85 (11)	0.000
Total	101 (20)	87 (12)	0.000

Data are given as median (interquartile range).




Figure 1 Triglycerides and glucose index as related to the number of components of metabolic syndrome in the overall study population.

After stratification by sex, a good correlation was found between the TyG index and the TG/HDL-C ratio in both men and women (Spearman's $\rho = 0.903$ and 0.883). AUC was greater than 0.75 in both cases. The cut-off points discriminating MS were 8.8 and 8.7 for men and women respectively in the TyG index; the corresponding values for the TG/HDL-C were 3.1 and 2.2 for men and women respectively.

Table 4 shows the indicators used to determine the discriminatory capacity of the cut-off points obtained for the TyG index and the TG/HDL-C ratio in the study groups.

Discussion

In this study, in agreement with previously reported data,^{8,14-16} the TyG index had a normal distribution in the study population, which is advantageous for statistical analysis and the interpretation of data. By contrast, the TG/HDL-C ratio followed a nonparametric distribution.

Mean TyG index and median TG/HDL-C ratio were markedly higher in subjects *with* MS as compared to those

Table 2 Results of the triglycerides and glucose index and the triglycerides/HDL-C ratio in the assessed groups (with and without metabolic syndrome).

Variable	Group		p (effect size)
	With metabolic syndrome (n = 89)	Without metabolic syndrome (n = 436)	
<i>Triglycerides and glucose index</i>			
Men	9.2 ± 0.6	8.3 ± 0.5	0.000 (Cohen's "d" = 1.6)
Women	9.0 ± 0.5	8.1 ± 0.5	0.000 (Cohen's "d" = 1.8)
Total	9.1 ± 0.6	8.3 ± 0.5	0.000 (Cohen's "d" = 1.6)
<i>Triglycerides/HDL cholesterol</i>			
Men	4.4 (3.1)*	2.0 (1.8)*	0.000 (Cliff's delta = 0.6)
Women	3.6 (2.4)*	1.4 (0.9)*	0.000 (Cliff's delta = 0.8)
Total	4.2 (3.0)*	1.8 (1.5)*	0.000 (Cliff's delta = 0.7)

Data are given as mean ± standard deviation and (*) as median (interquartile range).

without MS. In the latter group, 95% of subjects had TyG index values lower than the 50th percentile of the index in the group of subjects with MS. Mean TyG index also increased as the number of MS components increased, and a good correlation was found between the TyG index and the TG/HDL-C ratio.

These data are consistent with prior evidence supporting the value of the TyG index and the TG/HDL-C ratio as IR markers. Guerrero-Romero et al.¹⁴ suggested, based on their study in a population with and without changes in glucose metabolism, that the TyG index could be helpful for assessing IR because it showed a high sensitivity (96.5%) and specificity (85.0%) when it was assessed as compared to the hyperinsulinemic–euglycemic clamp. Abbasi and Reaven⁸ also concluded, in a study conducted on a non-diabetic population, that the TyG index and the TC/HDL-C ratio had a moderate correlation, as did indices using fasting insulin, with a direct method for assessing insulin-mediated glucose uptake, suggesting that alternative IR markers based

on lipid measurement are helpful for detecting subjects with IR when faced with the problems related to insulin measurement and action.

Because of the similarity of the cut-off points of the TyG index for discriminating MS in men (8.8) and women (8.7) found in this study, sex stratification may be considered as unnecessary, which is relevant for its use in daily clinical practice. In this regard, the TyG index of 8.8 obtained without sex stratification was the cut-off point with the greatest sensitivity and specificity for discriminating MS, and thus IR. Further studies are however needed to validate this index in other populations to generalize a cut-off value, taking into account the difficulties in obtaining access to reliable IR assessment.

For the TG/HDL-C ratio, the value discriminating MS in the overall population was 2.4, but in contrast to the TyG index, different values were seen after sex stratification. The cut-off points reported in this study were 2.2 for women and 3.1 for men, similar to the values reported by Salazar

Table 3 Values of percentiles of the triglycerides and glucose index in the assessed groups (with and without metabolic syndrome).

Group	Percentiles of the triglycerides and glucose index						
	5	10	25	50	75	90	95
<i>With metabolic syndrome</i>							
Men	8.2	8.5	8.9	9.1	9.5	9.8	10.3
Women	8.1	8.2	8.6	9.0	9.3	9.6	9.9
Total	8.2	8.4	8.9	9.1	9.4	9.8	10.0
<i>Without metabolic syndrome</i>							
Men	7.5	7.7	8.0	8.3	8.7	9.0	9.2
Women	7.3	7.5	7.8	8.2	8.4	8.6	8.9
Total	7.4	7.6	7.9	8.3	8.6	8.9	9.1

Table 4 Evaluation of the cut-off points found for the triglycerides and glucose index and for the triglycerides/cholesterol HDL ratio for discriminating metabolic syndrome.

	Triglycerides and glucose index			Triglycerides/HDL-C ratio		
	Men	Women	Total	Men	Women	Total
Cut-off point	8.8	8.7	8.8	3.1	2.2	2.4
Sensitivity	84%	72%	79%	77%	84%	88%
95% CI	75–94%	52–92%	70–88%	65–88%	68–100%	80–95%
Specificity	82%	91%	86%	74%	84%	72%
95% CI	78–87%	87–96%	83–88%	69–80%	78–90%	67–76%
Positive OR	4.8	8.2	5.8	3.0	5.3	3.1
95% CI	3.6–6.3	4.8–14.1	4.5–7.5	2.3–3.8	3.6–7.8	2.6–3.7
Negative OR	0.2	0.3	0.3	0.2	0.2	0.2
95% CI	0.1–0.3	0.2–0.6	0.2–0.4	0.2–0.5	0.1–0.5	0.1–0.3
Pre-test probability for MS	0.34	0.25	0.30	0.34	0.25	0.30
(%)	(34%)	(25%)	(30%)	(34%)	(25%)	(30%)
Positive post-test probability	0.71	0.73	0.72	0.61	0.64	0.58
(%)	(71%)	(73%)	(72%)	(61%)	(64%)	(58%)
Negative post-test probability	0.09	0.09	0.09	0.09	0.06	0.07
(%)	(9%)	(9%)	(9%)	(9%)	(6%)	(7%)

95% CI: 95% confidence interval, OR: odds ratio, MS: metabolic syndrome.

et al. to discriminate IR in an Argentine population (2.5 for women and 3.5 for men).¹⁶

ROC curve analysis showed that both the TyG index and the TG/HDL-C ratio were good at discriminating MS in the study population, showing a similar capacity to discriminate this condition. The cut-off point of the TyG index was more specific than the TG/HDL-C ratio for MS.

Evaluation of the diagnostic accuracy of the TyG index found that it was 5.8 times more likely that a result higher than 8.8 belongs to a subject *with MS* than to a subject *without MS*. This value converts the pre-test probability of 0.30 into a positive post-test probability of 0.72, which means that, in the study population, a subject with a TyG index

greater than 8.8 would have a 72% probability of having MS and/or, as a consequence, IR.

When the cut-off point of 2.4 of the TG/HDL-C ratio was evaluated in the total population, a higher cut-off point was found to be 3.1 times more likely to belong to a subject *with MS* than to a subject *without MS*, a lower probability than that found for the TyG index.

The positive post-test probability of having MS with a result higher than 2.4 was found to be 58%, which was lower than that obtained by the TyG index (72%).

In this study, upon sex stratification, positive post-test probabilities did not substantially differ from those of the overall population, and although the value of the TG/HDL-C ratio to discriminate MS slightly improved when the respective cut-off points for men and women were taken into consideration, it did not improve the performance of the TyG index.

On the other hand, the negative post-test probabilities of both parameters may be considered to be similar.

In addition to its value for discriminating MS, the TyG index has a methodological advantage over the TG/HDL-C ratio because it requires the measurement of glucose instead of HDL-C. The disadvantage of measuring HDL-C is that there are various methodological principles that still require clarification.

TGs, like insulin, have a great within-subject (19.9%) and between-subject biological variability (32.7%),⁴ but unlike insulin measurement, the testing of TG by enzymatic methods is standardized and analytically and financially accessible to all clinical laboratories. The TyG index therefore has an analytical advantage over indices using insulin measurement to assess IR.

As regards the limitations of this study, potential biases may include an imperfect reference test because of the lack of direct IR measurement and the fact that subjects were




Figure 2 ROC curve for the triglycerides and glucose index and the triglycerides/HDL cholesterol ratio as a function of the presence of metabolic syndrome in the study population.

assessed only once, so that within-subject biological variability of biochemical and clinical measurements could not therefore be minimized.

Based on the foregoing, it can be stated that the TyG index may be considered to be very helpful for IR assessment in the population. The simplicity of calculation of the TyG index from two routine, low cost biochemical measurements warrants further investigation of its role as an alternative evaluator of IR in order to improve the detection of subjects with a high cardiometabolic risk and so facilitate the prevention of the development of chronic diseases associated with IR.

Conflicts of interest

The authors state that they have no conflicts of interest.

References

- Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. *Am Heart J.* 2005;149 Suppl. 1:33–45.
- Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. *Am J Physiol Endocrinol Metab.* 2008;294:E15–26. Available from: <http://ajpendo.physiology.org/content/294/1/E15> [serie en Internet]. 2008 Ene [citado 12.02.14].
- Singh B, Saxena A. Surrogate markers of insulin resistance: a review. *World J Diabetes.* 2010;1:36–47. Available from: <http://www.wjgnet.com/1948-9358/full/v1/i2/36.htm> [serie en Internet] [citado 12.02.14].
- Westgard QC. Desirable biological variation database specifications; © 2009 [approx. 8 pp.] Available from: <http://www.westgard.com/biodatabase1.htm> [portal en Internet] [actualizado 24 Mar 2014; citado 2 Abr 2014].
- Staten MA, Stern MP, Miller WG, Steffes MW, Campbell SE, for the Insulin Standardization Workgroup. Insulin assay standardization leading to measures of insulin sensitivity and secretion for practical clinical care. *Diabetes Care.* 2010;33 Suppl. 1:205–6.
- Chen Z, Caulfield MP, McPhaul MJ, Reitz RE, Taylor SW, Clarke NJ. Quantitative insulin analysis using liquid chromatography–tandem mass spectrometry in a high-throughput clinical laboratory. *Clin Chem.* 2013;59 Suppl. 9:1349–56.
- Borai A, Livingstone C, Kaddam I, Ferns G. Selection of the appropriate method for the assessment of insulin resistance. *BMC Med Res Methodol.* 2011;158:1–10. Available from: <http://www.biomedcentral.com/content/pdf/1471-2288-11-158.pdf> [serie en Internet] [citado 14.02.14].
- Abbasi F, Reaven GM. Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides \times glucose versus triglyceride/high-density lipoprotein cholesterol. *Metabolism.* 2011;60:1673–6.
- Reaven G. ATVB in focus metabolic: syndrome and insulin resistance: mechanisms and consequences. Insulin resistance and coronary heart disease in nondiabetic individuals. *Arterioscler Thromb Vasc Biol.* 2012;32:1754–9.
- Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. *Endocrinol Metab Clin North Am.* 2005;34:49–62.
- Otero YF, Stafford JM, McGuinness OP. Pathway-selective insulin resistance and metabolic disease: the importance of nutrient flux. *J Biol Chem.* 2014. Available from: <http://www.jbc.org/content/early/2014/06/06/jbc.R114.576355.full.pdf> [serie en Internet] [citado 10.06.14].
- Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation.* 2011;123:01–42.
- Roa Barrios M, Arata-Bellabarba G, Valeri L, Velázquez-Maldonado E. Relación entre el cociente triglicéridos/C-HDL, índices de resistencia a la insulina y factores de riesgo cardiometabólico en mujeres con síndrome del ovario poliquístico. *Endocrinol Nutr.* 2009;56 Suppl. 2:59–65.
- Guerrero Romero F, Simental Mendia LE, Gonzalez Ortiz M, Martinez Abundis E, Ramos Zavala MG, Hernandez Gonzalez SO, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic–hyperinsulinemic clamp. *J Clin Endocrinol Metab.* 2010;95:3347–51.
- Irace C, Carallo C, Scavelli FB, De Franceschi MS, Esposito T, Tripolino C, et al. Markers of insulin resistance and carotid atherosclerosis. A comparison of the homeostasis model assessment and triglyceride glucose index. *Int J Clin Pract.* 2013;67 Suppl. 7:665–72.
- Salazar MR, Carbajal HA, Espeche WG, Leiva Sisniegues CE, March CE, Balbín E, et al. Comparison of the abilities of the plasma triglyceride/high-density lipoprotein cholesterol ratio and the metabolic syndrome to identify insulin resistance. *Diab Vasc Dis Res.* 2013;10 Suppl. 4:346–52.
- Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. *Panminerva Med.* 2005;47:201–10.
- Oda E. Metabolic syndrome: its history, mechanisms, and limitations. *Acta Diabetol.* 2012;49:89–95.
- Grundty SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. *J Am Coll Cardiol.* 2012;59:635–43.
- Tsatsoulis A, Mantzaris MD, Bellou S, Andrikoula M. Insulin resistance: an adaptive mechanism becomes maladaptive in the current environment – an evolutionary perspective. *Metabolism.* 2013;62:622–33.
- Coniglio RI, Nelles J, Gentili R, Sibechi N, Agusti E, Torres M. Síndrome metabólico en empleados en la Argentina. *Medicina (Buenos Aires).* 2009;69:246–52.
- López Fernández V, Suárez García S, Díaz González L, Álvarez Cosmea A, Arias García MT, Álvarez Menéndez F. Relación entre la proteína C reactiva ultrasensible y el síndrome metabólico en una población semiurbana española. *Clin Invest Arterioscl.* 2006;18 Suppl. 3:75–81.
- López De La Torre M, Bellido Guerrero D, Vidal Cortada J, Soto González A, García Malpartida K, Hernandez-Mijares A. Distribución de la circunferencia de la cintura y de la relación circunferencia de la cintura con respecto a la talla según la categoría del índice de masa corporal en los pacientes atendidos en consultas de endocrinología y nutrición. *Endocrinol Nutr.* 2010;57 Suppl. 10:479–85.
- Grundty SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. *Circulation.* 2005;112:2735–52.
- Becker LA. Effect size Calculators [portal en Internet]. Colorado Springs: University of Colorado Colorado Springs; © 1998–1999 [actualizado 20 Mar 2000; citado 15 Ene 2014]. College of Letters, Arts and Sciences; [approx. 2 pp.]. Available from: <http://www.uccs.edu/~lbecker/>
- Macbeth G, Razumiejczyk E, Ledesma RD. Cliff's Delta calculator: a non-parametric effect size program for two groups

- of observations. *Universitas Psychologica*. 2011;10 Suppl. 2:545-55.
27. Cerdá J, Cifuentes L. Uso de curvas ROC en investigación clínica. Aspectos teórico-prácticos. *Rev Chil Infect*. 2012;29 Suppl. 2:138-41.
28. Macchi RL. *Introducción a la Estadística en Ciencias de la Salud*. 2.^a ed. Buenos Aires: Editorial Médica Panamericana; 2013.
29. Mateo MM, Campos OH, Borges FN, Navarro Giné A. *Fundamentos de estadística en ciencias de la salud*. Bellaterra: Universitat Autònoma de Barcelona; 2010.